Frequency and prediction of deep uterine involvement in advanced high-grade epithelial ovarian cancer: is uterine preservation an option?


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
02 2021
Historique:
received: 11 07 2020
revised: 16 09 2020
accepted: 18 09 2020
pubmed: 12 11 2020
medline: 24 12 2021
entrez: 11 11 2020
Statut: ppublish

Résumé

Hysterectomy is traditionally part of the surgical treatment for advanced high-grade epithelial ovarian carcinomas, although the incidence of uterine involvement has not been fully investigated. Some young patients with advanced high-grade epithelial ovarian carcinomas want uterine preservation. We aimed to determine the frequency of non-serosal (deep) uterine involvement in patients with high-grade epithelial ovarian carcinomas and to establish predictive factors for such involvement. A retrospective cohort study was performed of 366 consecutive patients with advanced high-grade epithelial ovarian carcinomas who had surgery between January 2012 and December 2019. Data collected included demographic and clinical details, and surgical and pathological reports to determine macroscopic and microscopic deep uterine involvement. The characteristics of the patients with and without deep uterine involvement were compared and univariate and multivariate Cox proportional hazard models were used to assess correlations and determine risk factors. A total of 311 patients were included in the final analysis. The mean age was 62±11.6 years, with 32 (10.3%) being younger than 45. Most (92.3%) had serous carcinoma. Uterine involvement, excluding superficial (serosa-only), was present microscopically in 194 patients (62.4%) but was detected macroscopically at surgery in only 166 patients. Deep involvement was missed at surgery in 28 patients (14.4%), including parametrial involvement (n=18), parametria plus cervix (n=2), cervical involvement (n=3), endometrium (n=3), and myometrium (n=2). Multivariate analysis identified factors associated with deep uterine involvement including residual disease at surgery (HR 2.43, 95% CI 1.13 to 4.48; p=0.004) and CA125 >1000 U (HR 1.8, 95% CI 1.09 to 2.94; p=0.02). The incidence of deep uterine involvement in high-grade epithelial ovarian carcinomas is high. It can be diagnosed in most but not all cases on gross examination at surgery and is associated with residual disease and CA125 >1000 U. Patients who desire uterine preservation should be advised on an individual basis, given these factors and the operative findings.

Identifiants

pubmed: 33172922
pii: ijgc-2020-001850
doi: 10.1136/ijgc-2020-001850
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-256

Informations de copyright

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Tamar Perri (T)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel tamarperri@gmail.com.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Gal Harel (G)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Tal Dadon (T)

Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Aya Mor-Sasson (A)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Itai Yagel (I)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Gilad Ben-Baruch (G)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Jacob Korach (J)

Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH